The Real骔orld Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

S Akpinar, MH Dogu, S Celik, O Ekinci… - … Myeloma and Leukemia, 2022 - Elsevier
Abstract Introduction/Background The emergence of novel agents targeting the B-cell
receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL …
被引用次数：5 相关文章

The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

S Akpinar, MH Dogu, S Celik, O Ekinci, IY Hindilerden… - 2022 - acikerisim.sakarya.edu.tr
We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with
relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months …

The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

S Akpinar, M Dogu, S ÇELİK, O Ekinci… - CLINICAL …, 2022 - avesis.istanbul.edu.tr
We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with
relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months …

The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

S Akpinar, M Dogu, S ÇELİK, O Ekinci… - CLINICAL …, 2022 - avesis.inonu.edu.tr
We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with
relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months …

The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

S Akpinar, M Dogu, S Celik, O Ekinci… - Clinical Lymphoma …, 2022 - avesis.gazi.edu.tr
© 2021 Elsevier Inc. Introduction/Background: The emergence of novel agents targeting the
B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of …

The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

S Akpınar, MH Doğu, S Çelik, Ö Ekinci… - Clinical Lymphoma …, 2022 - acikerisim.nku.edu.tr
Introduction/Background: The emergence of novel agents targeting the B-cell receptor
pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We …

The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

S Akpinar, M Dogu, S Celik, O Ekinci… - Clinical Lymphoma …, 2022 - avesis.deu.edu.tr
Introduction/Background: The emergence of novel agents targeting the B-cell receptor
pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We …

The Real骔orld Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

S Akpinar, MH Dogu, S Celik… - Clinical …, 2022 - clinical-lymphoma-myeloma …
Abstract Introduction/Background The emergence of novel agents targeting the B-cell
receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL …

The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

S Akpinar, MH Dogu, S Celik, O Ekinci… - … Myeloma & Leukemia, 2022 - gcris.pau.edu.tr
We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with
relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months …

The Real骔orld Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

S Akpinar, M Dogu, S ÇELİK, O Ekinci… - Clinical Lymphoma …, 2022 - avesis.aybu.edu.tr
© 2021 Elsevier Inc. Introduction/Background: The emergence of novel agents targeting the
B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of …